Active Ingredient History
Strontium SR-89 is a radioactive isotope of strontium. Strontium-89 decays by beta emission with a half-life of 50.5 days. Beta-particles produced by radioactive decay penetrate tissues at a range of approximately 8 mm. Strontium SR-89 is used in medicine for the relief of bone pain in patients with painful skeletal metastases. Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Neoplasm Metastasis (approved 1993)
Amputation Stumps (Phase 2)
Bone Diseases, Metabolic (Phase 1)
Breast Neoplasms (Phase 3)
Erythema (Phase 1)
Lung Neoplasms (Phase 3)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 4)
Osteoarthritis (Phase 3)
Osteoporosis (Phase 1)
Pain (Phase 3)
Prostatic Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
